NIKKEI 225
38,708.12 -147.25 (-0.38%) HANG SENG
18,581.77 -239.39 (-1.27%) CRUDE OIL
80.14 +0.31 (+0.39%) GOLD FUTURES
2,357.90 +1.40 (+0.06%) DOW
38,852.86 -216.74 (-0.55%) Bitcoin GBP
53,675.20 -131.96 (-0.25%)
Alimera Sciences, Inc. (ALIM)
| Previous close | 2.9500 |
| Open | 2.9500 |
| Bid | 3.0700 x 100 |
| Ask | 3.1500 x 100 |
| Day's range | 2.9500 - 3.1750 |
| 52-week range | 2.4600 - 4.3800 |
| Volume | |
| Avg. volume | 67,954 |
| Market cap | 163.452M |
| Beta (5Y monthly) | 1.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2500 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.00 |
- GuruFocus.com
Alimera Sciences Inc (ALIM) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues and ...
Discover how Alimera Sciences achieved remarkable revenue growth and strategic advancements in Q1 2024.
ZacksAlimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -200% and 2.99%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireAlimera Sciences Reports First Quarter 2024 Results
Net Revenue up 70% to $23 Million vs. Q1 2023Global End User Demand Up 23% vs. Q1 2023Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter of 2024. Alimera will host a
